The use of advanced treatment technologies for prostate cancer has increased among men with low-risk disease, researchers found, despite uncertainty that these patients will benefit from these treatments.
In a retrospective review of men diagnosed with prostate cancer between 2004 and 2009, the use of advanced technologies, such as intensity-modulated radiotherapy (IMRT), increased from 32 percent to 44 percent among those with low-risk disease (P<0.001) and from 36 percent to 57 percent among those with high risk of noncancer mortality (P<0.001), according to Brent Hollenbeck, MD, of the University of Michigan in Ann Arbor, and colleagues.
